跳至主要内容
临床试验/NCT04920643
NCT04920643已完成不适用

High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery (ULTRA): A Canadian Randomized Controlled Trial

IWK Health Centre1 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2021年9月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
104
试验地点
1
主要终点
Peak Vasoactive-Ventilation Renal Score

研究概览

简要总结

Malformations of the heart are common; 1.35 million infants are born each year with congenital heart disease. Many of these defects carry a considerable threat to the individual's quality of life as well as survival. Along with focused medical management, surgical repair remains a standard of care for more than 25,000 infants and children each year in the United States and Canada. The care of individuals with congenital heart disease is highly complex and has significant risks of morbidity and mortality. Most cardiac operations require the use of cardiopulmonary bypass (CPB, also known as the heart-lung machine) to safely access the inner chambers of the heart. CPB itself has been well documented to cause significant inflammation and hemodilution as the individual's blood is passed through a foreign circuit. This inflammatory response can lead to fluid overload, distributive shock and potential end-organ dysfunction in the heart, lungs, kidneys, brain, liver or bowels. These organ dysfunctions may culminate in post-operative low cardiac output syndrome (LCOS), prolonged ventilation time, prolonged intensive care unit (ICU) stay and can contribute to mortality.

Dampening the inflammatory response from CPB has been a focus of research interest for years. Intra-operative ultrafiltration has been used to remove excess fluids and filter off inflammatory cytokines during cardiac operations. Over 90% of children's heart centers in the world utilize some form of ultrafiltration (mostly some form of modified ultrafiltration), but there are wide variations in published ultrafiltration protocols (none of which are combination SBUF-SMUF in children). Ultimately, this project seeks to provide high-quality evidence that the immunologic and clinical effects of combination SBUF-SMUF are rate dependent. Therefore, a randomized study directly comparing a high-exchange SBUF-SMUF (60ml/kg/hr) and a low-exchange SBUF-SMUF (6ml/kg/hr) can identify which is the optimal ultrafiltration protocol to enhance post-operative clinical outcomes for this patient population. The expected data and results could be immediately applicable to improve recovery after heart surgery for infants and children across Canada and the rest of the world at large.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • Congenital heart patients (2.5 - 15kg) have consented for a planned cardiac surgery procedure requiring cardiopulmonary bypass.
  • Parent or legal substitute decision-maker informed written consent to participate in the study.

排除标准

  • Patient or family refusal to participate.
  • Patient over 15kg (Fontan or Glenn patients will be considered up to 18kg)
  • No planned use of cardiopulmonary bypass
  • Isolated ASD repair
  • Known severe hematologic abnormality such as sick cell anemia, thalassemia, haemophilia A or B, von Willebrand disease or other.
  • Known genetic syndrome with severe neurologic or multi-organ abnormalities and immune dysfunction such as DiGeorge Syndrome, Trisomy 18 or 13, Noonan syndrome. (Trisomy 21 may be included in the study).
  • Known immunodeficiency syndrome or bone marrow pathology.
  • Severe liver or renal disease.

结局指标

主要结局

Peak Vasoactive-Ventilation Renal Score

时间窗: Up to 5 days

次要结局

  • Ventilation Index(Up to 5 days)
  • Ventilator Free Days(Up to 28 days)
  • Low Cardiac Output Syndrome(Up to 3 days)
  • Vasoplegic Shock(Up to 3 days)
  • C-Reactive Protein Concentrations(Measured at 1 day)
  • Vasoactive Inotrope Score(Up to 5 days)
  • Ventilation Time(Up to 28 days)
  • Vasoactive-Ventilation Renal Score(Up to 5 days)
  • Oxygenation Index(Up to 5 days)
  • Inotrope Free Days(Up to 28 days)
  • Cytokine Concentration (Patient Plasma)(Up to 1 day)
  • Lactate(Up to 5 days)
  • Creatinine(Up to 5 days)
  • Inotrope Dependence(Up to 2 days)
  • Loop Diuretic Use(Up to 7 days)
  • Peak Ventilation Index(Up to 5 days)
  • Haptoglobin (Plasma)(Up to 1 day)
  • Complete blood count(Up to 5 days)
  • Composite Outcome of mechanical circulatory support, acute renal failure, prolonged intubation and operative mortality.(Up to 30 days)
  • Inotrope Time(Up to 28 days)
  • Acute Kidney Injury(Up to 28 days)
  • Peak Vasoactive-Inotrope Score(Up to 5 days)
  • Peak Oxygenation Index(Up to 5 days)
  • Prolonged Intubation(Up to 28 days)
  • ICU Length of Stay(Up to 30 days)
  • Hospital Length of Stay(Up to 60 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. David Horne

Congenital Cardiac Surgeon

IWK Health Centre

研究点 (1)

Loading locations...

相似试验